Chronic Lower Back Pain Market Scope, Share Analysis And Growth 2025

Built for executives and teams involved in growth planning, this research offers a data-driven view of the chronic lower back pain industry’s direction and competitive environment.

How Large Will The Chronic Lower Back Pain Market Be By 2025?
The chronic lower back pain market size has grown steadily in recent years. It will grow from $7.72 billion in 2024 to $8.04 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to sedentary lifestyles, manual labor and occupational risks, medical advancements in diagnosis, pain management evolution, epidemiological studies.

The chronic lower back pain market size is expected to see steady growth in the next few years. It will grow to $9.63 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to rise in non-pharmacological interventions, preventive healthcare initiatives, focus on holistic treatments, regenerative medicine development, aging population trends. Major trends in the forecast period include focus on non-pharmacological interventions, shift in pain management approaches, healthcare awareness and education, telemedicine and remote monitoring, integration of regenerative medicine.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9946&type=smp

What Are Key Factors Driving The Demand In The Global Chronic Lower Back Pain Market?
An increase in the frequency of nerve instances is expected to propel the growth of the chronic lower back pain market. Nerve instances refer to specific occurrences or situations where someone displays bravery, courage, or resilience in the face of a challenging or daunting circumstance. Continuous exposure to stress and pain might lead to a phenomenon called central sensitization. This essentially means the nervous system becomes hypersensitive, perceiving pain more intensely, even in the absence of an actual injury. For instance, in July 2023, according to Nature, a UK-based weekly scientific journal, the prevalence of peripheral neuropathy, which is associated with nerve damage, is reported to be 28.4% in adults aged 40 or older with diabetes and 11.8% in those without diabetes. Therefore, an increase in the frequency of nerve instances is driving the growth of the chronic lower back pain market.

Comparative Analysis Of Leading Chronic Lower Back Pain Market Segments
The chronic lower back painmarket covered in this report is segmented –

1) By Type Of Pain: Diskogenic Pain; Lumbar Spinal Stenosis; Sacroiliac Pain; Facet-Joint Pain; Radicular Pain; Muscular Pain; Other Types Of Pain
2) By Diagnosis: Clinical History; Physical Examination; Imaging Guidelines; Assessment Of Pain
3) By End-User: Hospitals; Orthopedic Clinics; Ambulatory Surgery Centers; Other End-Users

Subsegments:
1) By Diskogenic Pain: Herniated Disc; Degenerative Disc Disease; Disc Bulge; Lumbar Spinal Stenosis
2) By Lumbar Spinal Stenosis: Central Stenosis; Lateral Stenosis
3) By Sacroiliac Pain: Sacroiliac Joint Dysfunction; Inflammatory Conditions
4) By Facet-Joint Pain: Facet Joint Syndrome; Osteoarthritis Of The Facet Joints
5) By Radicular Pain: Sciatica; Nerve Root Compression
6) By Muscular Pain: Muscle Strain; Muscle Spasm
7) By Other Types of Pain: Myofascial Pain Syndrome; Spondylolisthesis; Osteoporosis-Related Pain

What Are The Key Trends Shaping The Chronic Lower Back Pain Industry?
Major Companies operating in the chronic lower back pain market are focusing on developing innovative drugs to treat their customers and sustain their position in the market. The development of new drugs can improve treatment outcomes for patients with various diseases. For instance, in July 2022, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched LYVISPAH, a baclofen oral granule (5, 10, and 20 mg) approved by the U.S. Food and Drug Administration (FDA) for the treatment of spasticity that is related to multiple sclerosis and other spinal cord disorders. LYVISPAH treats and relieves flexor spasms and associated pain, clones, and muscular rigidity. It provides flexible, tailored dosage with single-dose packages of granules in doses of 5 mg, 10 mg, and 20 mg and is bioequivalent to oral baclofen tablets. Patients with spinal cord injuries and other spinal cord diseases may also benefit from using LYVISPAH.

Who Are The Prominent Players In The Chronic Lower Back Pain Business?
Major companies operating in the chronic lower back pain market include Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Endo Pharmaceuticals plc, Merck Corporation, Vertebral Technologies Inc., Medtronic plc, Boston Scientific Corporation, BioWave Corporation, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., SpineThera Inc., Dr. Reddy's Laboratories Ltd., Celgene Corporation, Axsome Therapeutics Inc., Mesoblast Limited, Frontier Biotechnologies Inc., Eli Lilly and Company, Persica Pharmaceuticals, Abbott Laboratories, Hisamitsu Pharmaceutical Co. Inc., Ipsen S.A., Daiichi Sankyo Company Ltd., Zimmer Biomet Holdings Inc., Novartis International AG, Janssen Pharmaceuticals Inc., Insys Therapeutics Inc., Collegium Pharmaceutical Inc., Cara Therapeutics Inc.

View the full chronic lower back pain market report here:
https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Which Region Is Expected To Lead The Chronic Lower Back Pain Market By 2025?
North America was the largest region in the chronic lower back pain market in 2024. The regions covered in the chronic lower back pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company